SS Innovations International (NASDAQ: SSII) announced a significant update on the expansion and utilization of its SSi Mantra surgical robotic system, reporting 14,103 cumulative procedures as of Sept. 8, 2026. This represents a 79% increase from 7,885 procedures at the end of 2025. The installed base of SSi Mantra systems grew 42% to 238 units, up from 168 at year-end 2025. These metrics underscore the company's accelerating traction in the global surgical robotics market.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the platform. The system has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the system's versatility and its potential to bring advanced surgical care to underserved regions.
SS Innovations also reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of Aug. 31, including a telesurgery spanning more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India. Such feats demonstrate the system's reliability and efficiency, which are critical for widespread adoption.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. It also believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are essential for entering major markets and competing with established players. The full report is available at https://ibn.fm/DJILj.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the proprietary SSi Mantra surgical robotic system and the comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
